Background {#Sec1}
==========

Viruses are the predominant cause of acute respiratory infection worldwide, being responsible for a high rate of morbidity and mortality especially in children, the elderly, and immunosuppressed patients \[[@CR1]--[@CR3]\].

Human Parainfluenzaviruses (PIVs) account for a significant proportion of viral acute respiratory infections (ARIs) in children, representing the second most common cause of upper and lower respiratory tract infections, behind Respiratory Syncytial Virus (RSV) \[[@CR4]\]. Both PIVs and RSV have also been associated with morbidity and mortality in adults, including nosocomial infections \[[@CR5]\].

There are four known types of PIV; PIV types 1 and 3 belong to the genus Respirovirus, while types 2 and 4 are from the genus Rubulavirus \[[@CR6]--[@CR8]\].

However, little information on the epidemiology and clinical characteristics of the different types of PIV infection has been published, especially works that consider adults and children separately.

A prospective, descriptive study was carried out in order to better characterize the different PIV types and their clinical features in children and adults with acute respiratory infection.

Study design {#Sec2}
============

Patients and samples {#Sec3}
--------------------

Between December 2016 and December 2017, 6121 respiratory samples (3689 pharyngeal, 137 nasal swabs, 2027 nasopharyngeal swabs, 160 low respiratory tract samples, and 108 from nasopharyngeal washing) were collected and taken, in viral transport medium (ViralPack, Biomedics, Spain) to the Clinical Virology Laboratory of the Hospital Universitario Central de Asturias (HUCA). Samples were from 4264 children (\< 16 years) and 1845 adults (aged \> 65), of whom 328 were immunosuppressed (oncology or hematology patients). Symptomatology of the samples corresponded to 1926 upper respiratory tract infections (URTIs), 681 lower respiratory tract infections (LRTIs), and 317 asthma cases and 3197 systemic symptoms (febrile syndrome, lymphadenopathies, and other respiratory infections not classified as URTI/LRTI).

Laboratory diagnosis {#Sec4}
--------------------

The samples were processed following laboratory protocols and were each then divided into two aliquots. The first (1 ml) was used for conventional monolayer cell culture (MRC-5 and mix of LLC-MK2, A549 and Hep-2), while the second (500 μl) was used for nucleic acid extraction. Quantitative real-time reverse transcription PCR (qRT-PCR) analyses were performed using type-specific primer pairs and MGB probes designed to target either the conserved regions of the matrix gene of PIV1/3 or of the polymerase gene of PIV2/4 in order to identify the strains of PIV present in the various respiratory samples.

Genomic detection, typing, and viral load {#Sec5}
-----------------------------------------

Nucleic acids were extracted using the automated purifier MagNAPure 96 (Roche Diagnostics, Mannheim, Germany) following the manufacturer's instructions. The extracted nucleic acids were then resuspended in a final volume of 70 μl.

PIV1--4 genome was detected by a multiplex qRT-PCR for Parainfluenzavirus genus, along with Metapneumovirus and Coronavirus genus (as per the protocol of the laboratory). Briefly, 5 μl of extracted nucleic acid was amplified, in a final volume of 10 μl, with TaqMan Fast 1-Step Master Mix (Life technologies, CA), four PIV primers (Thermo Fisher Scientific, MA), and two PIV FAM-labeled MGB probes (ABI, CA) (Table [1](#Tab1){ref-type="table"}). qRT-PCR amplification comprised an initial retrotranscription at 45 °C for 15 min, followed by a denaturation cycle at 95 °C for 10 min, and 40 amplification cycles consisting of 95 °C for 10 s and annealing/extension at 60 °C for 30 s. Amplifications were achieved in a 7300 or 7500 Real Time PCR System (Applied Biosystems).Table 1Parainfluenzavirus (PIV) primer and probe sequencesVirusGenePrimerSequence (5′-3′)SizeMGB probeSequence (5′-3′)PIV1MatrixPara1-SCATGTACATGCAACAGGCACATTA123 pbPara13-FAMTTTGTTATCCYTTAATGGATPara1-ATGAAGCTGCCCAGATGACTAGAPIV3Para3-SCATGTCAATGCAACTGGATCCATA123 pbPara3-ATGATGAAGCCCAGATAACCAGAPIV2PolymerasePara2/4-STATGTWGGTGAYCCRTTYAATCCT164 pbPara24-FAMGGAGGTATYGAAGGWCTPara2-AGCTGAAGAGAGGATGATCACAGAPIV4Para2/4-STATGTWGGTGAYCCRTTYAATCCT175 pbPara4-ATCTTAGATTCTGCAGATGACAAYAA

A standard curve was performed using serial dilutions from 10 to 10^10^ of amplicon-based positive controls of each type of PIV to determine the sensitivity of the assay. The limit of detection was 10 copies. In any run, positive controls were included and the Ct had to be between 27 and 33: 30--33 for PIV-1, 28--31 for PIV2, 27--30 for PIV3, and 28--31 for PIV4.

The specificity was evaluated using viral strains frequently found in human respiratory infections such as Influenza types A and B, Adenovirus, Metapneumovirus, Coronavirus, Rhinovirus, and Enterovirus as well as other viruses like CMV, EBV, HSV1, VZV, HHV6, HHV7, or Parvovirus.

Viral and cell quantification were performed by interpolating Ct data from qPCR assays of β-globin and of each virus genotype in a standard curve, as described previously \[[@CR9], [@CR10]\]. Viral load was calculated as the ratio of copies of viral genome/number of cells and expressed as (log~10~) copies/10^3^ cells. Infection and viral load data was then compared by age group, clinical manifestations, and seasonality.

Four different qRT-PCR assays, which included the FAM-labeled MGB probe and separate primers for PIV1, PIV2, PIV3, and PIV4 (Table [1](#Tab1){ref-type="table"}), were carried out to characterize Parainfluenzavirus type.

Statistical analyses {#Sec6}
--------------------

Statistical tests were performed using GraphPad InStat v.3. for Windows 2007 (GraphPad Software, USA). Tests were considered significant when *p* value was \< 0.05.

Results {#Sec7}
=======

Demographic data {#Sec8}
----------------

Of the samples from 6121 patients included in the study, viruses were detected in 2326. Enterovirus was the most frequently detected viral agent 742 (12.1%), followed by Adenovirus 621 (10.14%). Less frequent were Rhinovirus in 285 samples (4.6%), RSV in 242 (3.9%), Coronavirus in 178 (2.9%), and Influenza A (IA) in 143 (2.3%). Influenza B (B) was detected in 75 (1.2%) and Metapneumovirus in 40 (0.65%). Parainfluenzavirus infection was confirmed in 268 (4.37%) samples, a similar rate to RSV, of which 223 (5.23%) corresponded to samples from children and 45 (2.43%) from adults (*p* \< 0.0001) (26 (2.46%) aged between 16 and 65 and 19 (2.5%) older than 65) (Table [2](#Tab2){ref-type="table"} and Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}). Furthermore, 17 (5.18%) of the 328 immunosuppressed patients tested positive, a rate similar to that in the child population (*p* = 0.44).Table 2Incidence and distribution of Parainfluenzavirus by type, age, and viral loadTotal (*n*:268)VLChildren (*n*:223)Adults (*n*:45)*p*Incidence4.37%5.23%2.43%\< 0.0001VL5.3 ± 1.2 (2.4--9.5)5.3 ± 1.5 (2.4--9.5)5.6 ± 1.3 (2.6--8.4)nsPIV187 (32.5%)4.6 ± 1.3 (2.9--8.4)74 (33.2%)13 (28.9%)nsPIV27 (2.6%)4.7 ± 0.9 (3.6--5.9)5 (2.2%)2 (4.4%)nsPIV383 (31%)5.3 ± 1 (3.6--8.2)68 (30.5%)15 (33.3%)nsPIV438 (14.2%)5.6 ± 0.8 (4.1--7.6)33 (14.8%)5 (11.1%)nsPIVNT53 (19.8%)5 ± 1.4 (2.4--9.5)43 (19.3%)10 (22.2%)nsp\< 0.0001nsnsnsVL viral load (log~10~) copies/10^3^ cells, NT not typedFig. 1Distribution (percentage) of PIV type according to ageFig. 2Viral load of the different types of Parainfluenzavirus

PIV1/PIV3 were more frequent than PIV4/PIV2 (found in 32.5/31% compared to 14.2/2.6% of cases, respectively), although the distribution of the various types was similar in children and adults, as were viral loads (*p* = ns) (Table [3](#Tab3){ref-type="table"}). No patients were found to have more than one type of PIV.Table 3Distribution of types of PIV by season, showing viral load for each seasonWinter 2016/2017 (*n*:2176)Spring 2017 (*n*:1557)Summer 2017 (*n*:1092)Fall 2017 (*n*:1296)*p*PIV15 (0.23%)18 (1.15%)42 (3.86%)22 (1.69%)\< 0.0001PIV24 (0.18%)02 (0.18%)1 (0.08%)nsPIV325 (1.15%)46 (2.95%)3 (0.27%)9 (0.69%)\< 0.004PIV43 (0.14%)1 (0.06%)6 (0.55%)28 (2.16%)\< 0.002PIVNT18 (0.82%)20 (1.28%)6 (0.55%)9 (0.69%)nsTotal55 (2.52%)85 (5.46%)59 (5.4%)69 (5.32%)\< 0.0001VL5.1 ± 1.2 (2.9--9.5)5.3 ± 1 (2.6--8.2)5.4 ± 1.3 (2.9--8.4)5.6 ± 1.1 (2.4--8.3)\< 0.0001VL viral load (log~10~) copies/10^3^ cells, NT not typed

The genotype detected in the 17 immunosuppressed patients with PIV infection, were 8 (47.06%) cases of PIV3, 7 (41.17%) of PIV1, 1 (5.88%) of PIV2, and 1 of (5.88%) PIV4.

Seasonality {#Sec9}
-----------

Distribution and viral load of PIV-positive samples are shown in Table [3](#Tab3){ref-type="table"} and Figs. [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}.Fig. 3Distribution of PIV types across seasonsFig. 4PIV viral load by season

As Table [3](#Tab3){ref-type="table"} demonstrates, the season with the lowest levels of circulating Parainfluenzavirus is during winter (*p* \< 0.0001). In terms of genotypes, positive PIV3 samples were far more frequent in winter and spring, while a peak in PIV1-infected patients was noted in summer and PIV4 cases were significantly more common in fall, when, in addition, overall PIV viral load was higher than in other seasons (*p* \< 0.0001).

Clinical diagnosis {#Sec10}
------------------

Table [4](#Tab4){ref-type="table"} shows PIV infection rate and viral load by clinical status for each PIV type. No single clinical status was more predominantly associated with PIV infection: Parainfluenzavirus was detected in 103 (5.35%) cases of URTI, 34 (4.99%) cases of LRTI, 12 (3.78%) of asthma, and in 119 (3.72%) cases presenting systemic symptoms (febrile syndrome, lymphadenopathies, and other cases not classified as URTI/LRTI) (*p* = ns).Table 4Clinical diagnosis and viral load of patients with Parainfluenzavirus infectionURTI (*n*:1926)LRTI (*n*:681)Asthma (*n*:317)Systemic symptoms (*n*:3197)*p*PIV 134 (1.77%)8 (1.17%)4 (1.26%)41 (1.28%)nsPIV 22 (0.1%)1 (0.15%)1 (0.32%)3 (0.09%)nsPIV 339 (2.02%)10 (1.47%)3 (0.95%)31 (0.97%)nsPIV 414 (0.73%)7 (1.03%)1 (0.32%)16 (0.5%) nsPIV NT14 (0.73%)8 (1.17%)3 (0.95%)28 (0.87%)nsTotal PIV103 (5.35%)34 (4.99%)12 (3.78%)119 (3.72%)nsVL5.35 ± 1.17 (3.1--9.5)5.1 ± 1.2 (2.9--7.6)5.33 ± 1.3 (2.9--7.9)5.38 ± 1.19 (2.4--8.4)nsVL viral load (log~10~) copies/10^3^ cells, NT not typed

Infection rates ranged from 3.72% for systemic symptoms to 5.35% in cases of URTI (*p* = ns) and viral load varied between 5.1 (log~10~) copies/10^3^ cells in LRTI and 5.38 (log~10~) copies/10^3^ cells in systemic symptoms (*p* = ns).

Discussion {#Sec11}
==========

Respiratory infections are a major health challenge around the world. The causative agent in 80% of such infections are viruses, including PIV \[[@CR11]\]. Although PIVs are commonly recognized as a significant cause of morbidity and mortality in children, their impact in adults is less well characterized \[[@CR12]\]. In adults, PIVs usually cause mild URTIs, although they can also lead to life-threatening LRTIs and death in transplant recipients, as well as nosocomial infections and nursing-home outbreaks \[[@CR13]\], similar to the Influenza virus \[[@CR14]--[@CR17]\].

The efficacy of Ribavirin in the treatment of PIVs is limited and can be contradictory \[[@CR18]\]. Therefore, the early and accurate diagnosis of the viral agent continues to be a priority in order to prevent secondary bacterial infection, which increases morbidity and mortality, as well as the unnecessary use of antibiotics \[[@CR19]\].

In the present work, the most frequently found viruses were Enterovirus and Adenovirus with rates of 12.1 and 10.14%, respectively. The prevalence of PIVs was 4.37%, similar to Rhinovirus (4.6%) and RSV (3.9%). Children had significantly higher rate of infection than adults, although the lower rate in adults is in line with the rates of infection of the other viruses studied here. The rate of infection among immunosuppressed patients was found to be very similar to that of children.

In terms of PIV type, our results show that PIV1 and PIV3 were the most frequent genotypes. However, PIV4 in our study was more frequent than PIV2, a result not observed in the US study. The same distribution pattern for the different PIV genotypes was found in both adults and children, as well as in immunosuppressed patients, as also found in a study of adults and children in the USA between 1990 and 2004 \[[@CR13]\].

PIVs have been estimated to cause 10% of ARIs during the winter \[[@CR20]--[@CR22]\]. However, the results of our study indicate that in fact, for this type of clinical manifestation, PIV is circulating at lower rates (approximately 2%) in winter than during the rest of the year (approximately 5%). In addition, while it has been described in the literature that clinical manifestations of PIV vary depending upon the viral genotype involved, our findings do not support this. We did however find evidence of seasonal differences in the incidence of PIV genotypes: PIV3 being more common in spring, and winter, PIV1 in summer and PIV4 in fall, with PIV2 being present at only very lower rates in all seasons except spring, when it is totally absent. These findings are in contrast to those of other studies where no such seasonal effect has been observed for PIV4 since historically this genotype was considered to only be associated with mild respiratory problems and as such was not included in the diagnosis of ARIs.

Despite associations between PIV4 and ARIs having been proposed for more than half a century, it is not commonly included in clinical diagnoses, although some studies do highlight its potential virulence \[[@CR23], [@CR24], [@CR25]\]. We, however, found this virus to be circulating among both pediatric and adult patients presenting with different types of symptoms across the entire period tested, along with other PIV types, with PIV4 occurrence peaking in fall.

However, the most novel, and controversial in terms of diagnostics, finding from our study relates to viral load. The results provide evidence that in fall PIVs are circulating with a higher viral load than at other times in the year. As shown in Table [2](#Tab2){ref-type="table"}, in fall, while it is not significant, the viral load of PIV4 is slightly higher than the other genotypes. At the same time, rate of infection of PIV4 is significantly higher in fall. These two factors, greater incidence of PIV4 and its concomitant higher viral load, may well be the explanation for this interesting novel finding. As well as needing to corroborate these findings, further studies, with a greater number of samples, are also required to examine the possible link between viral load and the severity of clinical symptoms.

In addition, the results of this work provide evidence for the same rates of PIV infection in mild URTIs and LRTIs, as well as evidencing that clinical manifestations are not dependent on viral genotype or a specific viral load, thus distinguishing it from other studies \[[@CR26], [@CR27]\], something which could perhaps be corroborated with a greater number of patients.

In summary, this study provides evidence that PIVs cause respiratory infections in all age groups, albeit that, as has been found in other studies, children are more commonly affected, and we also show that virus replication is more efficient in fall. It is, however, important to note that, at least in our study scenario, PIVs are not only related to mild infections, such as those of the upper respiratory tract. In addition, it was observed that PIV4, on which there are very few studies because of the assumption it is related only to mild symptoms, was not only frequent, but was also associated with lower respiratory tract infections. The results presented here support the notion that testing for PIV type could provide additional valuable information as regards the distribution of the genotypes in terms of age and pathology, as well as seasonal differences in these data.
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